Side effect management during immune checkpoint blockade using CTLA‐4 and PD‐1 antibodies for metastatic melanoma–an update
KC Kähler, JC Hassel, L Heinzerling… - JDDG: Journal der …, 2020 - Wiley Online Library
Summary CTLA‐4 and PD‐1 play a key role in tumor‐induced downregulation of
lymphocytic immune responses. Immune checkpoint inhibitors have been shown to alter the …
lymphocytic immune responses. Immune checkpoint inhibitors have been shown to alter the …
Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma-an update
KC Kähler, JC Hassel, L Heinzerling… - … = Journal of the …, 2020 - pubmed.ncbi.nlm.nih.gov
CTLA-4 and PD-1 play a key role in tumor-induced downregulation of lymphocytic immune
responses. Immune checkpoint inhibitors have been shown to alter the immune response to …
responses. Immune checkpoint inhibitors have been shown to alter the immune response to …
Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma-an update.
KC Kähler, JC Hassel, L Heinzerling… - … = Journal of the …, 2020 - europepmc.org
CTLA-4 and PD-1 play a key role in tumor-induced downregulation of lymphocytic immune
responses. Immune checkpoint inhibitors have been shown to alter the immune response to …
responses. Immune checkpoint inhibitors have been shown to alter the immune response to …
[引用][C] Side effect management during immune checkpoint blockade using CTLA‐4 and PD‐1 antibodies for metastatic melanoma–an update
KC Kähler, JC Hassel, L Heinzerling, C Loquai… - 2020 - publications.goettingen-research …